CR8035A - Composiciones que contienen piperacilina y tazobactam utiles para inyecciones - Google Patents

Composiciones que contienen piperacilina y tazobactam utiles para inyecciones

Info

Publication number
CR8035A
CR8035A CR8035A CR8035A CR8035A CR 8035 A CR8035 A CR 8035A CR 8035 A CR8035 A CR 8035A CR 8035 A CR8035 A CR 8035A CR 8035 A CR8035 A CR 8035A
Authority
CR
Costa Rica
Prior art keywords
piperacilin
injections
compositions containing
tazobactam
useful
Prior art date
Application number
CR8035A
Other languages
English (en)
Inventor
Marc Cohen Jonathan
Muzafar Shah Syed
Luther Ofslager Christian
Bakir Fawzi Mahdi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8035(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR8035A publication Critical patent/CR8035A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se ha comprobado que un agente quelante de acido aminocaboxilico, de preferencia EDTA o una sal con el mismo compuesto, resultan utiles para inhibir la formacion de particulas en combinaciones parenterales de piperacilina , tazobactam. Asimismo, la composicion puede contener un buffer, de preferencia un citrato y un aminoglicosidode manera opcional.
CR8035A 2003-04-14 2005-10-07 Composiciones que contienen piperacilina y tazobactam utiles para inyecciones CR8035A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46280803P 2003-04-14 2003-04-14

Publications (1)

Publication Number Publication Date
CR8035A true CR8035A (es) 2006-05-30

Family

ID=32326726

Family Applications (2)

Application Number Title Priority Date Filing Date
CR8035A CR8035A (es) 2003-04-14 2005-10-07 Composiciones que contienen piperacilina y tazobactam utiles para inyecciones
CR9792A CR9792A (es) 2003-04-14 2008-03-04 Composiciones que contienen piperacilina y tazobactam utiles para inyecciones (divisional de exp. 8035)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR9792A CR9792A (es) 2003-04-14 2008-03-04 Composiciones que contienen piperacilina y tazobactam utiles para inyecciones (divisional de exp. 8035)

Country Status (34)

Country Link
US (3) US7498312B2 (es)
EP (1) EP1468697B1 (es)
JP (1) JP4644659B2 (es)
KR (1) KR100824554B1 (es)
CN (1) CN1802179B (es)
AR (1) AR043863A1 (es)
AT (1) ATE381947T1 (es)
AU (1) AU2004229407B2 (es)
BR (1) BRPI0409450B8 (es)
CA (1) CA2464258C (es)
CH (1) CH695185A9 (es)
CL (1) CL2004000782A1 (es)
CO (1) CO5700796A2 (es)
CR (2) CR8035A (es)
CY (1) CY1108064T1 (es)
DE (1) DE602004010862T2 (es)
DK (1) DK1468697T3 (es)
EC (1) ECSP056100A (es)
ES (1) ES2298672T3 (es)
FR (1) FR2853547B1 (es)
GB (1) GB2400557B (es)
IL (1) IL171337A (es)
MX (1) MXPA05010996A (es)
MY (1) MY139099A (es)
NO (1) NO20054789L (es)
NZ (1) NZ543005A (es)
PL (1) PL1468697T3 (es)
PT (1) PT1468697E (es)
RU (2) RU2322980C2 (es)
SA (1) SA04250119B1 (es)
SI (1) SI1468697T1 (es)
TW (1) TWI308069B (es)
WO (1) WO2004091666A1 (es)
ZA (1) ZA200508315B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3597262B1 (en) * 2002-12-20 2023-12-27 Xeris Pharmaceuticals, Inc. Formulation for intracutaneous injection
PT1468697E (pt) * 2003-04-14 2008-03-05 Wyeth Corp Composições contendo piperacilina e tazobactam úteis para injecção
WO2006044600A1 (en) * 2004-10-14 2006-04-27 Wyeth Compositions containing piperacillin, tazobactam and a aminocarboxilic acid in a sodium lactate diluent
CN101060846A (zh) * 2004-12-02 2007-10-24 维纳斯药业有限公司 采用可用于注射的β－内酰胺酶抑制剂防止β－内酰胺酶介导抗生素抗性的成分
ES2284318B1 (es) * 2005-04-13 2008-11-01 Labiana Development, S.L. Procedimiento de obtencion de una mezcla en polvo de una sal sodica de piperaciclina y tazobactama, util para su administracion por via inyectable.
ITMI20051630A1 (it) * 2005-09-02 2007-03-03 Acs Dobfar Spa Formulazione farmaceutica sterile iniettabile contenente almeno due principi attivi
CN1927201B (zh) * 2006-08-25 2011-06-01 天津和美生物技术有限公司 含哌拉西林的抗生素复方
CN101129383B (zh) * 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
CN101129381B (zh) * 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN102441169A (zh) * 2006-08-25 2012-05-09 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN101129382B (zh) * 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
CN102210679B (zh) * 2006-08-25 2013-03-13 天津和美生物技术有限公司 含哌拉西林的抗生素复方
CN101265263B (zh) * 2008-05-12 2010-06-02 海南百那医药发展有限公司 哌拉西林钠他唑巴坦钠复方注射剂的生产方法
WO2010013640A1 (ja) * 2008-07-28 2010-02-04 Yamaguchi Keizo 感染症治療効果増強剤
JP5852316B2 (ja) * 2010-03-30 2016-02-03 富山化学工業株式会社 ピペラシリン含有懸濁液の製造法
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
PE20140716A1 (es) 2010-11-25 2014-07-12 Allecra Therapeutics Gmbh Compuestos y su usos
MX342675B (es) 2011-03-10 2016-10-07 Xeris Pharmaceuticals Inc Formulaciones estables para inyeccion parenteral de farmacos de peptido.
PL2773331T3 (pl) 2011-10-31 2016-08-31 Xeris Pharmaceuticals Inc Preparaty do leczenia cukrzycy
MY169816A (en) 2012-03-26 2019-05-16 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US8476425B1 (en) * 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
KR101816798B1 (ko) * 2012-10-19 2018-01-10 주식회사유한양행 피페라실린 또는 그의 염, 타조박탐 또는 그의 염 및 덱사메타손 포스페이트 또는 그의 염을 포함하는 국소투여용 약학 조성물
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140274997A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Cephalosporin pharmaceutical compositions
UA121298C2 (uk) 2013-03-15 2020-05-12 Мерк Шарп І Доум Корп. Антибіотична композиція на основі цефтолозану і тазобактаму
AU2014233637A1 (en) 2013-09-09 2015-03-26 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
KR101927114B1 (ko) 2014-02-07 2018-12-10 엑시테라 파마슈티컬스 인코퍼레이티드 치료 화합물 및 조성물
KR102428675B1 (ko) 2014-08-06 2022-08-02 엑스에리스 파머수티클스, 인크. 페이스트의 피내 및／또는 피하 주사를 위한 주사기, 키트, 및 방법
CN106714799A (zh) * 2014-10-08 2017-05-24 泽井制药株式会社 冷冻干燥制剂的制造方法
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
CA2983256A1 (en) * 2016-03-31 2017-10-05 Wockhardt Limited Antibacterial compositions
WO2018025248A1 (en) * 2016-08-05 2018-02-08 Jodas Expoim Private Limited Edta injection and process for making the same
ES2982668T3 (es) 2017-06-02 2024-10-17 Xeris Pharmaceuticals Inc Formulaciones de fármacos de moléculas pequeñas resistentes a la precipitación
US11110054B2 (en) * 2018-05-09 2021-09-07 Slayback Pharma Llc Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
CN112618486B (zh) * 2020-12-24 2023-07-18 浙江昂利康制药股份有限公司 一种注射用混悬油剂及其制备方法
CN113209030B (zh) * 2021-04-27 2023-04-25 海南通用康力制药有限公司 哌拉西林钠他唑巴坦钠无菌粉针剂的制备方法
CN119367287B (zh) * 2024-12-27 2025-03-28 成都硕德药业有限公司 一种重酒石酸去甲肾上腺素注射液及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477452A (en) * 1981-03-26 1984-10-16 American Cyanamid Company Composition of matter comprising a lyophilized preparation of a penicillin derivative
US4534977A (en) * 1981-03-26 1985-08-13 American Cyanamid Company Composition of matter comprising a low bulk density lyophilized preparation of Sodium Piperacillin
US4562073A (en) * 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
US5763480A (en) * 1994-02-14 1998-06-09 The Jewish Hospital Of St. Louis Inhibitors of cell-medicated disorders
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6207661B1 (en) 1999-02-22 2001-03-27 Baxter International Inc. Premixed formulation of piperacillin sodium and tazobactam sodium injection
AU2003225073A1 (en) * 2002-04-18 2003-11-03 The University Of Iowa Research Foundation Methods of inhibiting and treating bacterial biofilms by metal chelators
US6900184B2 (en) * 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
PT1468697E (pt) 2003-04-14 2008-03-05 Wyeth Corp Composições contendo piperacilina e tazobactam úteis para injecção
WO2004098643A1 (en) * 2003-04-14 2004-11-18 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection

Also Published As

Publication number Publication date
CL2004000782A1 (es) 2005-03-04
PL1468697T3 (pl) 2008-05-30
WO2004091666A1 (en) 2004-10-28
CY1108064T1 (el) 2014-02-12
US8133883B2 (en) 2012-03-13
US20110166091A1 (en) 2011-07-07
AU2004229407A1 (en) 2004-10-28
ES2298672T3 (es) 2008-05-16
ZA200508315B (en) 2008-04-30
KR20060014375A (ko) 2006-02-15
CO5700796A2 (es) 2006-11-30
DE602004010862D1 (de) 2008-02-07
RU2005135135A (ru) 2006-06-10
US7915229B2 (en) 2011-03-29
EP1468697A1 (en) 2004-10-20
CH695185A9 (fr) 2006-02-28
CH695185A5 (fr) 2006-01-13
KR100824554B1 (ko) 2008-04-24
BRPI0409450B8 (pt) 2021-05-25
MY139099A (en) 2009-08-28
WO2004091666A8 (en) 2005-11-10
RU2007142454A (ru) 2009-05-27
FR2853547A1 (fr) 2004-10-15
NO20054789D0 (no) 2005-10-18
ECSP056100A (es) 2006-03-01
NZ543005A (en) 2009-03-31
DK1468697T3 (da) 2008-04-14
TW200503758A (en) 2005-02-01
GB0407853D0 (en) 2004-05-12
EP1468697B1 (en) 2007-12-26
CA2464258A1 (en) 2004-10-14
CN1802179B (zh) 2011-09-14
NO20054789L (no) 2005-12-13
HK1069775A1 (en) 2005-06-03
CN1802179A (zh) 2006-07-12
PT1468697E (pt) 2008-03-05
JP4644659B2 (ja) 2011-03-02
AU2004229407B2 (en) 2010-04-22
CR9792A (es) 2008-09-23
TWI308069B (en) 2009-04-01
SA04250119B1 (ar) 2008-03-30
US7498312B2 (en) 2009-03-03
JP2006523695A (ja) 2006-10-19
DE602004010862T2 (de) 2009-01-02
GB2400557B (en) 2005-06-15
MXPA05010996A (es) 2005-12-12
US20060234995A1 (en) 2006-10-19
ATE381947T1 (de) 2008-01-15
US20090176720A1 (en) 2009-07-09
FR2853547B1 (fr) 2006-08-04
IL171337A (en) 2011-03-31
GB2400557A (en) 2004-10-20
BRPI0409450A (pt) 2006-05-02
AR043863A1 (es) 2005-08-17
RU2322980C2 (ru) 2008-04-27
SI1468697T1 (sl) 2008-04-30
BRPI0409450B1 (pt) 2016-07-12
CA2464258C (en) 2005-06-07

Similar Documents

Publication Publication Date Title
CR8035A (es) Composiciones que contienen piperacilina y tazobactam utiles para inyecciones
MY207044A (en) Antibodies for chelated radionuclides
BRPI0408382A (pt) composição contendo materiais de zinco particulado que têm um tamanho definido de cristalito
BRPI0414711A (pt) processo para a desoxidação de superfìcies metálicas, e, composições aquosa, ácida para a desoxidação de superfìcies metálicas
AR084185A1 (es) Composiciones dentifricas que contienen silicato de calcio y un aminoacido basico, metodo para el cuidado oral
MX2007007312A (es) Composiciones multifase estructuradas y suaves para la limpieza personal.
AR021049A1 (es) Una composicion detergente solida
BR9917282A (pt) Composição oral para inibição de mal odor oral
BR0215898A (pt) Composição e método para a formação não permanente durável de pelo menos uma fibra queratìnica ou para a retenção durável de uma forma não permanente de pelo menos uma fibra queratìnica e kit para proteger pelo menos uma fibra queratìnica contra danos extrìnsecos
HN2008000612A (es) Composiciones acidas para limpieza
AR065933A1 (es) Composicion para la higiene oral y su uso
MX2024011550A (es) Acido retardante monofasico a base de un tensioactivo anfotero
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
EA200401434A1 (ru) Обработка опасного, являющегося отходом, материала
MX2020009935A (es) Formulaciones acuosas y estables de anticuerpos anti-tau.
PA8684501A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
GB2434148A (en) Methods of extending the shelf life of and revitalizing lightweight beads for use in cement compositions
ATE475631T1 (de) Partikel eines geschmolzenen keramikmaterials
UA97346C2 (ru) Стабильная эмульсионная композиция
PE20220591A1 (es) Composicion farmaceutica que contiene acetaminofeno e ibuprofeno
AR044449A1 (es) Composiciones acuosas desinfectantes y/o bactericidas
CL2004000740A1 (es) Composicion solida blanda antitranspirante y/o desodorante que comprende: una solicona volatil y un compuesto de acido graso de behenamido alquil-quilamina de formula definida, como agente gelificante.
TW200505460A (en) Rosmarinic acid composition
MY142020A (en) Oral compositions for prevention and reduction of bacterial adhesion to oral surfaces
AR046320A1 (es) Composiciones farmaceuticas estabilizadas de dibenzo-oxepina.